James B Byrd1, Amy E Rothberg2, Robert Chomic3, Charles F Burant4, Robert D Brook1, Richard J Auchus5. 1. Division of Cardiovascular Medicine, Mich., USA. 2. Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, Mich., USA; Division of Weight Management Program, Mich., USA. 3. Division of Metabolomics Core, Mich., USA. 4. Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, Mich., USA; Division of Weight Management Program, Mich., USA; Division of Metabolomics Core, Mich., USA; Department of Molecular and Integrative Physiology, Mich., USA. 5. Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, Mich., USA; Division of Metabolomics Core, Mich., USA; Division of Pharmacology, University of Michigan, Ann Arbor, Mich., USA.
Abstract
BACKGROUND/AIMS: The pathogenesis of obesity-associated hypertension is poorly understood. Serum cortisol-to-cortisone ratio (F/E ratio) is a marker of cortisol metabolism. Our objective was to determine whether the serum F/E ratio is associated with blood pressure (BP) in patients after significant weight loss (≥15% from baseline weight). METHODS: Sera from 43 nondiabetic, severely obese males participating in a weight management program were assayed for F and E by mass spectrometry. We assessed whether changes in the F/E ratio accompanying weight loss correlate with changes in the systolic (SBP) and diastolic BP (DBP). Linear regression was used to evaluate change in the F/E ratio as a predictor of change in BP. RESULTS: The body mass index decreased from 40.8 ± 5.6 to 33.7 ± 4.8 (p < 0.001); also, SBP (133.2 ± 13.8 vs. 124.1 ± 14.3 mm Hg; p < 0.001) and DBP (69.8 ± 8.0 vs. 66.6 ± 9.4 mm Hg; p = 0.026) decreased during the study. The baseline F/E ratio tended to associate with baseline DBP (Spearman's r = -0.29, p = 0.06), and change in the serum F/E ratio correlated with change in DBP (Spearman's r = -0.32, p = 0.036). Change in the F/E ratio also tended to associate with change in SBP (Spearman's r = -0.27, p = 0.08). A multiple linear regression model adjusted for change in the F/E ratio and age explained 22% of the variance in SBP change (R(2) = 0.22, p = 0.007). Change in the F/E ratio independently predicted change in SBP (p = 0.036). CONCLUSION: In our sample of nondiabetic, severely obese males, change in the serum F/E ratio was associated with change in BP after weight loss.
BACKGROUND/AIMS: The pathogenesis of obesity-associated hypertension is poorly understood. Serum cortisol-to-cortisone ratio (F/E ratio) is a marker of cortisol metabolism. Our objective was to determine whether the serum F/E ratio is associated with blood pressure (BP) in patients after significant weight loss (≥15% from baseline weight). METHODS: Sera from 43 nondiabetic, severely obese males participating in a weight management program were assayed for F and E by mass spectrometry. We assessed whether changes in the F/E ratio accompanying weight loss correlate with changes in the systolic (SBP) and diastolic BP (DBP). Linear regression was used to evaluate change in the F/E ratio as a predictor of change in BP. RESULTS: The body mass index decreased from 40.8 ± 5.6 to 33.7 ± 4.8 (p < 0.001); also, SBP (133.2 ± 13.8 vs. 124.1 ± 14.3 mm Hg; p < 0.001) and DBP (69.8 ± 8.0 vs. 66.6 ± 9.4 mm Hg; p = 0.026) decreased during the study. The baseline F/E ratio tended to associate with baseline DBP (Spearman's r = -0.29, p = 0.06), and change in the serum F/E ratio correlated with change in DBP (Spearman's r = -0.32, p = 0.036). Change in the F/E ratio also tended to associate with change in SBP (Spearman's r = -0.27, p = 0.08). A multiple linear regression model adjusted for change in the F/E ratio and age explained 22% of the variance in SBP change (R(2) = 0.22, p = 0.007). Change in the F/E ratio independently predicted change in SBP (p = 0.036). CONCLUSION: In our sample of nondiabetic, severely obese males, change in the serum F/E ratio was associated with change in BP after weight loss.
Authors: Rena R Wing; Paula Bolin; Frederick L Brancati; George A Bray; Jeanne M Clark; Mace Coday; Richard S Crow; Jeffrey M Curtis; Caitlin M Egan; Mark A Espeland; Mary Evans; John P Foreyt; Siran Ghazarian; Edward W Gregg; Barbara Harrison; Helen P Hazuda; James O Hill; Edward S Horton; Van S Hubbard; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Maria G Montez; Anne Murillo; David M Nathan; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; David Reboussin; Judith G Regensteiner; Amy D Rickman; Donna H Ryan; Monika Safford; Thomas A Wadden; Lynne E Wagenknecht; Delia S West; David F Williamson; Susan Z Yanovski Journal: N Engl J Med Date: 2013-06-24 Impact factor: 91.245
Authors: C P Woods; M Corrigan; L Gathercole; A Taylor; B Hughes; G Gaoatswe; K Manolopoulos; A E Hogan; J O'Connell; P M Stewart; J W Tomlinson; D O'Shea; M Sherlock Journal: J Clin Endocrinol Metab Date: 2015-01-20 Impact factor: 5.958
Authors: Stefan Engeli; Jana Böhnke; Mareike Feldpausch; Kerstin Gorzelniak; Ute Heintze; Jürgen Janke; Friedrich C Luft; Arya M Sharma Journal: Obes Res Date: 2004-01
Authors: Amy E Rothberg; Laura N McEwen; Tom Fraser; Charles F Burant; William H Herman Journal: Obesity (Silver Spring) Date: 2013-10-17 Impact factor: 5.002
Authors: Johanna Maria Brix; Andrea Tura; Carsten Thilo Herz; Astrid Feder; Eva-Christina Krzizek; Verena Parzer; Giovanni Pacini; Bernhard Ludvik Journal: Obes Facts Date: 2021-09-08 Impact factor: 3.942